VIRMA and lung cancer: This intricate molecular interplay between KIAA1429, ARHGAP30, and the PI3K/AKT signaling pathway offers significant insights into the mechanistic pathways driving LUAD progression, highlighting potential targets for therapeutic intervention in this form of lung cancer.